Hepatitis B virus reactivation with rituximab-containing regimen

doi:10.4254/wjh.v5.i11.612

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5520)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

299

HTML

2688

Figures (1-1)

207

Tables (1-1)

212

Sum=3406

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1210

Download

904

Sum=2114

Nov 27, 2013 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Nov 27, 2013; 5(11): 612-620
Published online Nov 27, 2013. doi: 10.4254/wjh.v5.i11.612

Table 1 Analyzed patients were 18 males and 17 females, with 17 cases of diffuse large B-cell lymphoma and nine cases of follicular lymphoma

Characteristics of anti-HBs Ab positive patients
Age (yr)	67 (42-87)
Males/Females	18/17
Disease
DLB	17
FL	9
MCL	1
MALT	3
Burkitt lymphoma	1
EBV associated LPD	1
WM	1
CLL	2
Stage
I	3
II	3
III	7
IV	21
Chemotherapy
R-CHOP	10
R-THP-COP	20
R+VP16	1
R+MVP	1
R+TEOP	1
R+bendamustine	1
R	2
R-Course	10 (1-30)

In these patients, 21 were clinical stage IV. In 30 patients, the initial treatment consisted of 2 to 6 rounds of CHOP mainly combined with rituximab or THP-COP. DLB: Diffuse large B cell lymphoma; FL: Follicular lymphoma; MCL: Mantle cell lymphoma; MALT: Mucosa-associated lymphoid tissue; EBV: Epstein-Barr virus; LPD: Lymphoproliferative diseases; WM: Waldenstrom macroglobulinemia; CLL: Chronic lymphocytic leukemia.

Citation: Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5(11): 612-620
URL: https://www.wjgnet.com/1948-5182/full/v5/i11/612.htm
DOI: https://dx.doi.org/10.4254/wjh.v5.i11.612